Pfizer said today it has acquired BioRexis Pharmaceutical Corporation, a privately-held biopharmaceutical firm working on several diabetes treatments and a novel technology platform for new protein drug candidates. Financial terms of the deal were not disclosed. The technology being used to develop the experimental treatments relies on protein engineering and may have the potential to improve drug tolerability, reduce dosing frequency and improve patient compliance, Pfizer said.